T-Cypher Bio Announces Formation of Scientific Advisory Board
Oxford, UK, 29 July 2021 T-Cypher Bio (T-Cypher, or the Company), a rapidly emerging private biotech company pioneering a novel approach to TCR-based therapeutics, today announces the formation and members of its Scientific Advisory Board (SAB) comprising international leaders of T cell immunology.
- Oxford, UK, 29 July 2021 T-Cypher Bio (T-Cypher, or the Company), a rapidly emerging private biotech company pioneering a novel approach to TCR-based therapeutics, today announces the formation and members of its Scientific Advisory Board (SAB) comprising international leaders of T cell immunology.
- Thomas Lars Andresen, PhD, CEO said: I am delighted to welcome such a highly esteemed group of world leaders and experts in T cell immunology to the companys Scientific Advisory Board.
- Uciane Scarlett, PhD, Interim Executive Chair & OSI Investment Principal, said: The establishment of the Scientific Advisory Board marks a significant step for the T-Cypher team.
- The members of the Scientific Advisory Board are as follows:
Graham Ogg FMedSci is Professor of Dermatology at the University of Oxford.